MWN101注射液

Search documents
【公告全知道】创新药+脑机接口+减肥药+人工智能!公司MWN101注射液已完成肥胖二期临床试验
财联社· 2025-07-01 14:40
Group 1 - The article highlights significant announcements in the stock market from Sunday to Thursday, including "suspensions and resumption of trading, shareholding changes, investment wins, acquisitions, earnings reports, unlocks, and high transfers" [1] - Important announcements are marked in red to assist investors in identifying investment hotspots and preventing various black swan events, providing ample time for analysis and selection of suitable listed companies [1] Group 2 - A company has completed Phase II clinical trials for MWN101 injection, targeting obesity and Type II diabetes, indicating potential in the innovative drug sector [1] - Another company is leveraging its blockchain technology for applications related to digital RMB, showcasing its capabilities in stablecoins, blockchain, and internet finance [1] - A collaboration between a company and Huoshan Engine aims to develop specialized large models and several intelligent agents, reflecting advancements in AI and cross-border e-commerce [1]
乐普医疗(300003):2024年报、2025年一季报点评:25Q1环比改善,看好全年业绩修复
Orient Securities· 2025-04-30 05:52
25Q1 环比改善,看好全年业绩修复 ——乐普医疗 2024 年报&2025 年一季报点评 核心观点 盈利预测与投资建议 伍云飞 wuyunfei1@orientsec.com.cn 执业证书编号:S0860524020001 香港证监会牌照:BRX199 ⚫ 根据 24 年报及 25 年一季报,我们下调收入及毛利率预测,我们预测公司 2025-2027 年 EPS 分别为 0.54/0.61/0.67 元(原预测 25-26 年 EPS 为 0.75、0.90 元)。根据可 比公司 2025 年平均估值,给予公司 2025 年 23 倍市盈率,对应目标价为 12.42 元, 维持给予"买入"评级。 风险提示 ⚫ 研发进展和新产品商业化不及预期;集采或者市场竞争加剧带来的冲击;大额计提 减值风险。 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 7,980 | 6,103 | 6,835 | 7,378 | 7,968 | | 同比增长 (%) | ...